2024 ICD-10-CM Diagnosis Code T45.1X6D

Underdosing of antineoplastic and immunosuppressive drugs, subsequent encounter

ICD-10-CM Code:
T45.1X6D
ICD-10 Code for:
Underdosing of antineoplastic and immunosup drugs, subs
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Not chronic
Code Navigator:

Code Classification

  • Injury, poisoning and certain other consequences of external causes
    (S00–T88)
    • Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
      (T36-T50)
      • Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified
        (T45)

T45.1X6D is a billable diagnosis code used to specify a medical diagnosis of underdosing of antineoplastic and immunosuppressive drugs, subsequent encounter. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.

This code describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.

T45.1X6D is a subsequent encounter code, includes a 7th character and should be used after the patient has completed active treatment for a condition like underdosing of antineoplastic and immunosuppressive drugs. According to ICD-10-CM Guidelines a "subsequent encounter" occurs when the patient is receiving routine care for the condition during the healing or recovery phase of treatment. Subsequent diagnosis codes are appropriate during the recovery phase, no matter how many times the patient has seen the provider for this condition. If the provider needs to adjust the patient's care plan due to a setback or other complication, the encounter becomes active again.

Clinical Classification

Clinical Information

  • Aclarubicin

    an anthracycline produced by streptomyces galilaeus. it has potent antineoplastic activity.
  • Altretamine

    a hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.
  • Aminoglutethimide

    an aromatase inhibitor that is used in the treatment of advanced breast cancer.
  • Amsacrine

    an aminoacridine derivative that intercalates into dna and is used as an antineoplastic agent.
  • Anthramycin

    a broad-spectrum spectrum antineoplastic antibiotic isolated from streptomyces refuineus var. thermotolerans. it has low toxicity, some activity against trichomonas and endamoeba, and inhibits rna and dna synthesis. it binds irreversibly to dna.
  • Asparaginase

    a hydrolase enzyme that converts l-asparagine and water to l-aspartate and nh3. ec 3.5.1.1.
  • Azacitidine

    a pyrimidine analogue that inhibits dna methyltransferase, impairing dna methylation. it is also an antimetabolite of cytidine, incorporated primarily into rna. azacytidine has been used as an antineoplastic agent.
  • Azaserine

    antibiotic substance produced by various streptomyces species. it is an inhibitor of enzymatic activities that involve glutamine and is used as an antineoplastic and immunosuppressive agent.
  • Azathioprine

    an immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. according to the fourth annual report on carcinogens (ntp 85-002, 1985), this substance has been listed as a known carcinogen. (merck index, 11th ed)
  • Bleomycin

    a complex of related glycopeptide antibiotics from streptomyces verticillus consisting of bleomycin a2 and b2. it inhibits dna metabolism and is used as an antineoplastic, especially for solid tumors.
  • Carboplatin

    an organoplatinum compound that possesses antineoplastic activity.
  • Carmustine

    a cell-cycle phase nonspecific alkylating antineoplastic agent. it is used in the treatment of brain tumors and various other malignant neoplasms. (from martindale, the extra pharmacopoeia, 30th ed, p462) this substance may reasonably be anticipated to be a carcinogen according to the fourth annual report on carcinogens (ntp 85-002, 1985). (from merck index, 11th ed)
  • Chlorambucil

    a nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, hodgkin's disease, and others. although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the fourth annual report on carcinogens (ntp 85-002, 1985). (merck index, 11th ed)
  • Chromomycin A3

    glycosidic antibiotic from streptomyces griseus used as a fluorescent stain of dna and as an antineoplastic agent.
  • Cisplatin

    an inorganic and water-soluble platinum complex. after undergoing hydrolysis, it reacts with dna to produce both intra and interstrand crosslinks. these crosslinks appear to impair replication and transcription of dna. the cytotoxicity of cisplatin correlates with cellular arrest in the g2 phase of the cell cycle.
  • Cyclophosphamide

    precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. it has been used in the treatment of lymphoma and leukemia. its side effect, alopecia, has been used for defleecing sheep. cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
  • Arabinofuranosylcytosine Triphosphate

    a triphosphate nucleotide analog which is the biologically active form of cytarabine. it inhibits nuclear dna synthesis.
  • Cytarabine

    a pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of dna. its actions are specific for the s phase of the cell cycle. it also has antiviral and immunosuppressant properties. (from martindale, the extra pharmacopoeia, 30th ed, p472)
  • Dacarbazine

    an antineoplastic agent. it has significant activity against melanomas. (from martindale, the extra pharmacopoeia, 31st ed, p564)
  • Dactinomycin

    a compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. it binds to dna and inhibits rna synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. as a result of impaired mrna production, protein synthesis also declines after dactinomycin therapy. (from ama drug evaluations annual, 1993, p2015)
  • Carbonyl Reductase (NADPH)

    nadph-dependent reductase that catalyzes the reduction of many carbonyl compounds including quinones; prostaglandins; and xenobiotics.
  • Daunorubicin

    a very toxic anthracycline aminoglycoside antineoplastic isolated from streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
  • Demecolcine

    an alkaloid isolated from colchicum autumnale l. and used as an antineoplastic.
  • Doxorubicin

    antineoplastic antibiotic obtained from streptomyces peucetius. it is a hydroxy derivative of daunorubicin.
  • Epirubicin

    an anthracycline which is the 4'-epi-isomer of doxorubicin. the compound exerts its antitumor effects by interference with the synthesis and function of dna.
  • Estramustine

    a nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.
  • Etoposide

    a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. etoposide inhibits dna synthesis by forming a complex with topoisomerase ii and dna. this complex induces breaks in double stranded dna and prevents repair by topoisomerase ii binding. accumulated breaks in dna prevent entry into the mitotic phase of cell division, and lead to cell death. etoposide acts primarily in the g2 and s phases of the cell cycle.
  • Floxuridine

    an antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. it has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
  • Fluorouracil

    a pyrimidine analog that is an antineoplastic antimetabolite. it interferes with dna synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
  • Goserelin

    a synthetic long-acting agonist of gonadotropin-releasing hormone. goserelin is used in treatments of malignant neoplasms of the prostate, uterine fibromas, and metastatic breast cancer.
  • Hydroxyurea

    an antineoplastic agent that inhibits dna synthesis through the inhibition of ribonucleoside diphosphate reductase.
  • Idarubicin

    an orally administered anthracycline antineoplastic. the compound has shown activity against breast neoplasms; lymphoma; and leukemia.
  • Ifosfamide

    positional isomer of cyclophosphamide which is active as an alkylating agent and an immunosuppressive agent.
  • Lomustine

    an alkylating agent of value against both hematologic malignancies and solid tumors.
  • Mannomustine

    nitrogen mustard derivative alkylating agent used as antineoplastic. it causes severe bone marrow depression and is a powerful vesicant.
  • Mechlorethamine

    a biologic alkylating agent that exerts its cytotoxic effects by forming dna adducts and dna interstrand crosslinks, thereby inhibiting rapidly proliferating cells. the hydrochloride is an antineoplastic agent used to treat hodgkin disease and lymphoma.
  • Melphalan

    an alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - melphalan, the racemic mixture - merphalan, and the dextro isomer - medphalan; toxic to bone marrow, but little vesicant action; potential carcinogen.
  • Mercaptopurine

    an antimetabolite antineoplastic agent with immunosuppressant properties. it interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
  • Methotrexate

    an antineoplastic antimetabolite with immunosuppressant properties. it is an inhibitor of tetrahydrofolate dehydrogenase and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of dna.
  • Mitobronitol

    brominated analog of mannitol which is an antineoplastic agent appearing to act as an alkylating agent.
  • Mitoguazone

    antineoplastic agent effective against myelogenous leukemia in experimental animals. also acts as an inhibitor of animal s-adenosylmethionine decarboxylase.
  • Mitolactol

    alkylating antineoplastic toxic to bone marrow; used in breast cancer, also in combination with other drugs.
  • Mitomycin

    an antineoplastic antibiotic produced by streptomyces caespitosus. it is one of the bi- or tri-functional alkylating agents causing cross-linking of dna and inhibition of dna synthesis.
  • Mitomycins

    a group of methylazirinopyrroloindolediones obtained from certain streptomyces strains. they are very toxic antibiotics used as antineoplastic agents in some solid tumors. porfiromycin and mitomycin are the most useful members of the group.
  • Mitotane

    a derivative of the insecticide dichlorodiphenyldichloroethane that specifically inhibits cells of the adrenal cortex and their production of hormones. it is used to treat adrenocortical tumors and causes cns damage, but no bone marrow depression.
  • Mitoxantrone

    an anthracenedione-derived antineoplastic agent.
  • Mopidamol

    a phosphodiesterase inhibitor which inhibits platelet aggregation. formerly used as an antineoplastic.
  • Nimustine

    antineoplastic agent especially effective against malignant brain tumors. the resistance which brain tumor cells acquire to the initial effectiveness of this drug can be partially overcome by the simultaneous use of membrane-modifying agents such as reserpine, calcium antagonists such as nicardipine or verapamil, or the calmodulin inhibitor, trifluoperazine. the drug has also been used in combination with other antineoplastic agents or with radiotherapy for the treatment of various neoplasms.
  • Pentostatin

    a potent inhibitor of adenosine deaminase. the drug induces apoptosis of lymphocytes, and is used in the treatment of many lymphoproliferative malignancies, particularly hairy cell leukemia. it is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
  • Peplomycin

    an antineoplastic agent derived from bleomycin.
  • Pipobroman

    an antineoplastic agent that acts by alkylation.
  • Plicamycin

    a tricyclic pentaglycosidic antibiotic from streptomyces strains that inhibits rna and protein synthesis by adhering to dna. it is used as a fluorescent dye and as an antineoplastic agent, especially in bone and testicular tumors. plicamycin is also used to reduce hypercalcemia, especially that due to malignancies.
  • Porfiromycin

    toxic antibiotic of the mitomycin group, obtained from mitomycin and also from streptomyces ardus and other species. it is proposed as an antineoplastic agent, with some antibiotic properties.
  • Prednimustine

    ester of chlorambucil and prednisolone used as a combination alkylating agent and synthetic steroid to treat various leukemias and other neoplasms. it causes gastrointestinal and bone marrow toxicity.
  • Procarbazine

    an antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the mopp protocol) in the treatment of hodgkin's disease.
  • Dexrazoxane

    the (+)-enantiomorph of razoxane.
  • Razoxane

    an antimitotic agent with immunosuppressive properties.
  • Semustine

    4-methyl derivative of lomustine; (ccnu). an antineoplastic agent which functions as an alkylating agent.
  • Diabetes Mellitus, Experimental

    diabetes mellitus induced experimentally by administration of various diabetogenic agents or by pancreatectomy.
  • Streptozocin

    an antibiotic that is produced by stretomyces achromogenes. it is used as an antineoplastic agent and to induce diabetes in experimental animals.
  • Tegafur

    congener of fluorouracil with comparable antineoplastic action. it has been suggested especially for the treatment of breast neoplasms.
  • Teniposide

    a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. teniposide inhibits dna synthesis by forming a complex with topoisomerase ii and dna. this complex induces breaks in double stranded dna and prevents repair by topoisomerase ii binding. accumulated breaks in dna prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. teniposide acts primarily in the g2 and s phases of the cycle.
  • Thalidomide

    a piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. it has been reintroduced and used for a number of immunological and inflammatory disorders. thalidomide displays immunosuppressive and anti-angiogenic activity. it inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action.
  • Thioguanine

    an antineoplastic compound which also has antimetabolite action. the drug is used in the therapy of acute leukemia.
  • Thiotepa

    a very toxic alkylating antineoplastic agent also used as an insect sterilant. it causes skin, gastrointestinal, cns, and bone marrow damage. according to the fourth annual report on carcinogens (ntp 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (merck index, 11th ed).
  • Triaziquone

    alkylating antineoplastic agent used mainly for ovarian tumors. it is toxic to skin, gastrointestinal tract, bone marrow and kidneys.
  • Triethylenemelamine

    toxic alkylating agent used in industry; also as antineoplastic and research tool to produce chromosome aberrations and cancers.
  • Triethylenephosphoramide

    an insect chemosterilant and an antineoplastic agent.
  • Trimetrexate

    a nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. it is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in aids patients. myelosuppression is its dose-limiting toxic effect.
  • Uracil Mustard

    nitrogen mustard derivative of uracil. it is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage.
  • Urethane

    antineoplastic agent that is also used as a veterinary anesthetic. it has also been used as an intermediate in organic synthesis. urethane is suspected to be a carcinogen.
  • Vinblastine

    antitumor alkaloid isolated from vinca rosea. (merck, 11th ed.)
  • Vincamine

    a major alkaloid of vinca minor l., apocynaceae. it has been used therapeutically as a vasodilator and antihypertensive agent, particularly in cerebrovascular disorders.
  • Vincristine

    an antitumor alkaloid isolated from vinca rosea. (merck, 11th ed.)
  • Vindesine

    vinblastine derivative with antineoplastic activity against cancer. major side effects are myelosuppression and neurotoxicity. vindesine is used extensively in chemotherapy protocols (antineoplastic combined chemotherapy protocols).
  • Zinostatin

    an enediyne that alkylates dna and rna like mitomycin does, so it is cytotoxic.

Coding Guidelines

Underdosing refers to taking less of a medication than is prescribed by a provider or a manufacturer's instruction. Codes for underdosing should never be assigned as principal or first-listed codes. If a patient has a relapse or exacerbation of the medical condition for which the drug is prescribed because of the reduction in dose, then the medical condition itself should be coded.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified (T45). Use the following options for the aplicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Code Edits

The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10-CM Code Edits are applicable to this code:

  • Unacceptable principal diagnosis - There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Present on Admission (POA)

T45.1X6D is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here.

CMS POA Indicator Options and Definitions

POA IndicatorReason for CodeCMS will pay the CC/MCC DRG?
YDiagnosis was present at time of inpatient admission.YES
NDiagnosis was not present at time of inpatient admission.NO
UDocumentation insufficient to determine if the condition was present at the time of inpatient admission.NO
WClinically undetermined - unable to clinically determine whether the condition was present at the time of inpatient admission.YES
1Unreported/Not used - Exempt from POA reporting. NO

Convert T45.1X6D to ICD-9-CM

  • ICD-9-CM Code: -
    No Map Flag -

Table of Drugs and Chemicals

The parent code T45.1X6 of the current diagnosis code is referenced in the Table of Drugs and Chemicals, this table contains a classification of drugs, industrial solvents, corrosive gases, noxious plants, pesticides, and other toxic agents.

According to ICD-10-CM coding guidelines it is advised to do not code directly from the Table of Drugs and Chemicals, instead always refer back to the Tabular List when doing the initial coding. Each substance in the table is assigned a code according to the poisoning classification and external causes of adverse effects. It is important to use as many codes as necessary to specify all reported drugs, medicinal or chemical substances. If the same diagnosis code describes the causative agent for more than one adverse reaction, poisoning, toxic effect or underdosing, utilize the code only once.

Substance Poisoning
Accidental
(unintentional)
Poisoning
Accidental
(self-harm)
Poisoning
Assault
Poisoning
Undetermined
Adverse
effect
Underdosing
AclarubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Actinomycin CT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Actinomycin DT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AdriamycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Alkylating drug NECT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Alkylating drug NEC
  »antimyeloproliferative
T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Alkylating drug NEC
  »lymphatic
T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AltretamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AmethopterinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AminoglutethimideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Aminopterin sodiumT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AmsacrineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AnthramycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Anticancer agents NECT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AntimetaboliteT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antimitotic agentT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antineoplastic NECT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antineoplastic NEC
  »alkaloidal
T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antineoplastic NEC
  »antibiotics
T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antineoplastic NEC
  »combination
T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antineoplastic NEC
  »combination
    »estrogen
T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Antineoplastic NEC
  »steroid
T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Ara-CT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AsparaginaseT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AzacitidineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AzaribineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AzaserineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AzatepaT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
AzathioprineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
BCNUT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
BenzcarbimineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
BleomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
BroxuridineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Busulfan, busulphanT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CactinomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Cancer chemotherapy drug regimenT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CarboplatinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CarboquoneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CarmofurT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CarmustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ChlorambucilT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ChlorhexamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ChlormethineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ChloropurineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Chromomycin A3T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CiclosporinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CisplatinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ColaspaseT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Corynebacterium parvumT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CycloleucinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CyclophosphamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CyclosporinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CytarabineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Cytosine arabinosideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
CytoxanT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DacarbazineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DactinomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DaunomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DaunorubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DemecolcineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
2-Deoxy-5-fluorouridineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
5-Deoxy-5-fluorouridineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DibromodulcitolT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DibromomannitolT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DoxifluridineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DoxorubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
DTICT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Elliptinium acetateT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
EnocitabineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
EpirubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
EstramustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
EtoglucidT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
EtoposideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
FAC (fluorouracil + doxorubicin + cyclophosphamide)T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
FloxuridineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
FluorodeoxyuridineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
FluorouracilT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
FtorafurT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
GoldT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Gold
  »colloidal (l98Au)
T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Gold
  »salts
T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
GoserelinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
HexamethylmelamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
HydroxycarbamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
HydroxyureaT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
IdarubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
IfosfamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Imidazole-4-carboxamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Immunosuppressive drugT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
InproquoneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
IproplatinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
IsophosphamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
LeukeranT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
LomustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
LonidamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
M-AMSAT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MannomustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MatulaneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MechlorethamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MelphalanT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MercaptopurineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MethotrexateT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MetoprineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MithramycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitobronitolT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitoguazoneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitolactolT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitopodozideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitotaneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MitoxantroneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MopidamolT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MOPP (mechloreth-amine + vincristine + prednisone + procarba-zine)T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Muromonab-CD3T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
M-vacT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MyelobromalT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
MyleranT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
NimustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
OlivomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
OncovinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ParoxypropioneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PentostatinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PeplomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Phenylalanine mustardT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PipobromanT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PirarubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PlicamycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PorfiromycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PrednimustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ProcarbazineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PteroyltriglutamateT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Purine analogue (antineoplastic)T45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
PurinetholT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Pyrimidine antagonistT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
RazoxaneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
RubidomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
RufocromomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
SarcolysinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
SarkomycinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
SemustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
StreptozocinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
StreptozotocinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TauromustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TegafurT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TEMT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TeniposideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TEPAT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ThalidomideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ThioguanineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ThiotepaT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TioguanineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TreosulfanT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TretamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TriaziquoneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TrichlormethineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TrichlorotriethylamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TriethanomelamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TriethylenemelamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TriethylenephosphoramideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TriethylenethiophosphoramideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TrimetrexateT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TrimustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
TrofosfamideT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Uracil mustardT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
UramustineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
UrethaneT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
VinblastineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
VincamineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
VincristineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
VindesineT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
Vinorelbine tartrateT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ZinostatinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6
ZorubicinT45.1X1T45.1X2T45.1X3T45.1X4T45.1X5T45.1X6

Patient Education


Medication Errors

Medicines treat infectious diseases, prevent problems from chronic diseases, and ease pain. But medicines can also cause harmful reactions if not used correctly. Errors can happen in the hospital, at the health care provider's office, at the pharmacy, or at home. You can help prevent errors by:

  • Knowing your medicines. When you get a prescription, ask the name of the medicine and check to make sure that the pharmacy gave you the right medicine. Make sure that you understand how often you should take the medicine and how long you should take it.
  • Keeping a list of medicines.
    • Write down all of the medicines that you are taking, including the names of your medicines, how much you take, and when you take them. Make sure to include any over-the-counter medicines, vitamins, supplements, and herbs that you take.
    • List the medicines that you are allergic to or that have caused you problems in the past.
    • Take this list with you every time you see a health care provider.
  • Reading medicine labels and following the directions. Don't just rely on your memory - read the medication label every time. Be especially careful when giving medicines to children.
  • Asking questions. If you don't know the answers to these questions, ask your health care provider or pharmacist:
    • Why am I taking this medicine?
    • What are the common side effects?
    • What should I do if I have side effects?
    • When should I stop this medicine?
    • Can I take this medicine with the other medicines and supplements on my list?
    • Do I need to avoid certain foods or alcohol while taking this medicine?

Food and Drug Administration


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.